CAPTRUST Financial Advisors’s Heron Therapeutics HRTX Stock Holding History
Bought
Maintained
Sold
Other funds holding HRTX
CAPTRUST Financial Advisors's HRTX Position: Q3 2026 in Review
CAPTRUST Financial Advisors increased its Heron Therapeutics (HRTX) stake by 2.7% in Q3 2026, buying an estimated $532 and bringing the position to 52,950 shares worth $16.6K. The position accounts for ﹤0.01% of the portfolio, ranked #3334.
CAPTRUST Financial Advisors first reported a position in HRTX in Q3 2018 and has held it in 25 quarters since. The position peaked at $98.6K in Q2 2025. 158 funds tracked by Wall St. Rank hold HRTX as of Q3 2026.
- CAPTRUST Financial Advisors held 52,950 shares of Heron Therapeutics worth $16.6K as of Q3 2026.
- CAPTRUST Financial Advisors bought 1,403 Heron Therapeutics shares in Q3 2026, an estimated $532.
- Heron Therapeutics made up ﹤0.01% of CAPTRUST Financial Advisors's portfolio in Q3 2026, its #3334 holding.
- CAPTRUST Financial Advisors first reported a position in Heron Therapeutics in Q3 2018 and has held it in 25 quarters since.
- CAPTRUST Financial Advisors's Heron Therapeutics position peaked at $98.6K in Q2 2025.
- 158 funds tracked by Wall St. Rank held Heron Therapeutics as of Q3 2026.
Based on CAPTRUST Financial Advisors's 13F filing for Q3 2026, filed 12 Nov 2026.